Velocity Clinical Research, a multi-specialty clinical sites business, has appointed Rachael Buck Ph.D. as Country Head in the U.K.

Rachael will lead the five sites Velocity currently owns and operates in the U.K. and will work with the rest of Velocity’s European executive team to expand the company’s footprint in the British Isles. 
 
Rachael joins the company from Accellacare (ICON) where she was senior director of site networks. She has more than 20 years of experience in the industry, the majority of which has been in dedicated research site networks such as Synexus (AES), Medinova, and at CROs in the world, including Parexel. 
 
With experience in driving the growth of numerous sites and partnerships, Rachael previously oversaw global quality assurance, project management, the EMEA medical team, project technology and operational finance as a senior director of site networks at Accellacare. 
 
Dominic Clavell, Executive Vice President Europe at Velocity, said, “Velocity is proud to welcome Rachael as our new Country Manager, a testament to our commitment to attracting top talent from leading organizations in the clinical trials industry. We’re doing things differently at Velocity, changing the way the industry thinks about clinical research and streamlining the approach so that trials get done quicker. Rachael’s expertise will be instrumental in realizing our vision of creating a cohesive network of high-performing clinical trial sites across Europe. Her leadership will significantly enhance our efforts to scale operations in what has traditionally been a fragmented landscape.”